Preoperative C-reactive protein/albumin ratio predicts the prognosis of patients with resectable pancreatic cancer
10.3760/cma.j.issn.0529-5815.2018.09.013
- VernacularTitle: 术前C反应蛋白和清蛋白比值对可切除胰腺癌患者预后的影响
- Author:
Baoyang LUO
1
;
Yong YANG
;
Yunfei DUAN
;
Huihua CAI
;
Yong AN
;
Donglin SUN
Author Information
1. Department of Hepatobiliary and Pancreatic Surgery, the third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Prognosis;
C-reactive Protein/Albumin ratio
- From:
Chinese Journal of Surgery
2018;56(9):712-717
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical significance of C-reactive protein/albumin ratio in predicting the postoperative prognosis of pancreatic cancer patients.
Methods:The clinical date of 97 patients with resectable pancreatic cancers who treated at Department of Hepatobiliary and Pancreatic Surgery, the third Affiliated Hospital of Soochow University from January 2005 to December 2015 were analyzed retrospectively. The cut-off value of CRP/Alb ratio was determined by the receiver operating characteristic(ROC) curve. According to the CRP/Alb ratio, patients were respectively divided into two groups: the high group(CRP/Alb ratio≥0.109) and the low group(CRP/Alb<0.109). The relationships between CRP/Alb ratio and clinical characteristics were analyzed by χ2 test. Median survival and 1-year overall survival rate(OS) was calculated by Kaplan-Meier method.The risk factors of patients with poor prognosis were analyzed by univariate and multivariate Cox regression analysis model.
Results:Tumor TNM stage(χ2=4.280, P=0.039) and differentiation(χ2=6.635, P=0.010) had significant relationship with CRP/Alb ratio. The median survival of higher CRP/Alb ratio group and lower CRP/Alb ratio group was 15 months and 23 months respectively. Compared with lower CRP/Alb ratio group, the 1-year OS of higher CRP/Alb ratio group decreased remarkablely, and the difference was statistically(χ2=10.207, P=0.001). Moreover, median survival and OS were decreased in patients with advanced age(≥65 years old: χ2 =5.338, P=0.021), high TNM stage(ⅡB-Ⅲ: χ2 =10.529, P=0.001), poor tumor differentiation(χ2=5.380, P=0.020), vascular invasion(χ2 =7.856, P=0.005) and positive surgical margin(χ2=9.059, P=0.003). A high CRP/Alb ratio was identified as an independent risk factor of poor prognosis for patients with pancreatic cancer(HR=1.832, 95% CI: 1.067-3.144, P=0.028). Besides, old age(HR=1.684, P=0.014), high TNM stage(HR=1.666, P=0.031), vascular invasion(HR=1.834, P=0.024) and positive surgical margin(HR=2.205, P=0.023) were also included.
Conclusion:Preoperative CRP/Alb ratio can be an important clinical factor for assessing the prognosis of patients with resectable pancreatic cancers, and high CRP/Alb ratio suggests poor prognosis.
